Q3 Revenue Misses as Biologics Attachment Slips; FY26 Outlook Reset to $862M
ATEC sits 67% above its 52-week low of $6.82 on elevated volume (2.7× avg).
Summary
ATEC posted Q3 revenue of $221 million, up from $196.5 million a year ago, but management said the top line fell short of its own expectations because of lower biologics attachment. The miss is the story: hardware grew 17% and case volumes rose roughly 20%, so the procedure engine is working while the attach-rate economics are not. Profitability still improved — adjusted EBITDA of $38 million, a 17.3% margin, expanded 400 basis points year over year, and the company generated $6 million of free cash flow. GAAP net loss narrowed to $5 million from $28.6 million, with a loss per share of 3 cents. Guidance now calls for about $862 million of FY2026 revenue (roughly 13% growth), $137 million of adjusted EBITDA and $10 million of free cash flow. Watch whether management quantifies the biologics shortfall and the OsteoAdapt timeline on the 4:30 p.m. ET call — that is where the reset gets priced.
At the time of this announcement, ATEC was trading at $11.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $6.82 to $23.29. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.